Document:

Form of Securities Purchase Agreement

 EXHIBIT 10.1 
 Name:                                     
    
 Number:                         
 Securities Purchase Agreement 
 PRO-PHARMACEUTICALS, INC. 
 2007 Private Placement of Securities 
 This Securities Purchase Agreement (“Agreement”) is made by and between Pro-Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and the undersigned person (the “Subscriber”) who is subscribing hereby
for units of securities of the Company at one dollar ($1.00) per Unit, each unit comprised of (i) one share of the Company’s Series A Convertible Preferred Stock, par value $.01 per share (the “Preferred Stock”), (ii) a
warrant exercisable for four years at $1.50 per share to purchase one share of the Company’s common stock, par value $.001 per share (the “Common Stock”), and (iii) a warrant exercisable for four years at $2.00 per share to
purchase one share of Common Stock (collectively, the “Warrants”), pursuant to private placement offering documents of the Company comprised of (a) the Term Sheet containing certain terms applicable to the Units and this offering,
(b) Securities Purchase Agreement, (c) Accredited Investor Questionnaire (the “Investor Questionnaire”), (d) form of designation certificate for the Preferred Stock, (e) form of Warrant, and (e) Registration Rights
Agreement (collectively, the “Offering Documents”). 
 In consideration of the Company’s agreement to issue and sell to the
Subscriber the Units upon the terms and conditions set forth herein, the Subscriber agrees and represents as follows: 
  

	1.	Purchase. 

  

	 	A.	The Subscriber hereby agrees to purchase the number of Units set forth on the signature page below at a price of $1.00 per Unit. Simultaneously with the execution of this Purchase
Agreement, the Subscriber is paying to the Company the amount set forth on the signature page. 

  

	 	B.	The Subscriber hereby acknowledges receipt of the Offering Documents delivered in “hard copy” form. 

  

	 	C.	The Subscriber understands and acknowledges that: 

  

	 	(1)	This subscription may be accepted or rejected in whole or in part by the Company in its sole and absolute discretion. 

	 	(2)	This subscription is and shall be irrevocable except that the Subscriber shall have no obligations hereunder in the event that this subscription is for any reason rejected or this
offering is for any reason canceled. 

  

	 	(3)	No federal or state agency has made any finding or determination as to the fairness of this offering for investment, nor any recommendation or endorsement of the Shares.

  

	 	(4)	In order to purchase Shares, the Subscriber must qualify as an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933 (detailed in
Exhibit A hereto), and as evidenced by a duly completed and signed Investor Questionnaire. 

  

	 	D.	All pronouns used herein shall be deemed to refer to the masculine, feminine, neuter, singular or plural as the identity/ies of the person(s) or entity/ies may require.

  

	2.	Representations and Warranties. The Subscriber hereby represents, warrants and agrees that: 

  

	 	A.	The Units are being acquired by the Subscriber solely for his own personal account, for investment purposes only, and not with a view to, or in connection with, any resale or
distribution thereof; the Subscriber has no contract, undertaking, understanding, agreement or arrangement, formal or informal, with any person to sell, transfer or pledge to any person the Units for which he hereby subscribes, or any part, any
interest therein or any rights thereto; the Subscriber has no present plans to enter into any such contract, undertaking, agreement or arrangement; and he understands the legal consequences of the following representations and warranties to mean
that he must bear the economic risk of the investment for an indefinite period of time because the Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) and applicable state securities laws.

  

	 	B.	The Subscriber understands that neither the Units offered hereby, nor the shares of Common Stock issuable as dividends upon conversion or conversion of the Preferred Stock or upon
exercise of the Warrants (collectively, the “Underlying Shares”), have been registered under the Securities Act or any state securities laws and are being issued pursuant to an exemption from the registration requirements under the
Securities Act or applicable state securities law. 

  

	 	C.	The Subscriber understands that an investment in the Units involves substantial risk, and has fully considered for purposes of this investment that: 

  

	 	(1)	this investment is suitable only for an investor who is able to bear the economic consequences of losing his entire investment, 

	 	(2)	the purchase of the Units is a speculative investment which involves a high degree of risk of loss by the Subscriber of his entire investment, and 

  

	 	(3)	there may be substantial restrictions on the transferability of, and there will be no public market for, the Preferred Stock, the Warrants and the Underlying Shares and,
accordingly, it may not be possible for him to liquidate his investment in such securities in case of emergency. 

  

	 	D.	The Subscriber’s overall commitment to investments which are not readily marketable is not disproportionate to his net worth and his investment in the Units will not cause such
overall commitment to become excessive. 

  

	 	E.	The Subscriber has adequate net worth and means of providing for his current needs and personal contingencies to sustain a complete loss of his investment in the Preferred Stock,
the Warrants and the Underlying Shares, and is able to hold such securities for an indefinite period of time and has no need for liquidity in this investment in such securities. 

  

	 	F.	The Subscriber’s investment in the Units does not exceed 25% of his net worth, or joint net worth with the Subscriber’s spouse (excluding principal residence and
furnishings). 

  

	 	G.	The Subscriber has such knowledge and experience in financial and business matters the Subscriber is capable of evaluating the merits and risks of an investment in the Units and of
making an informed investment decision. If other than an individual, the Subscriber also represents it has not been organized for the purpose of acquiring the Units. 

  

	 	H.	The Subscriber has received and carefully read the Offering Documents. The Subscriber acknowledges that the Company has afforded him, or any person such as an attorney our
accountant acting on his behalf, the opportunity to ask questions and receive answers from the Company concerning the terms and conditions of the offering and to verify the accuracy of the information in the Offering Documents and the Company has
provided answers to all such questions and provided such documents as requested. In evaluating the suitability of an investment in the Units, the Subscriber has not relied upon any representations or other information (whether oral or written) other
than as set forth in the Offering Documents or as contained in answers to questions or documents so furnished to him by the Company. 

  

	 	I.	 The Subscriber is acquiring the Units without being furnished any offering literature or prospectus other than the Offering Documents and without reliance on any
representations or statements that may have been have 

	 	 
been made to the Subscriber by the Company, or any officer, employee, agent, affiliate or subsidiary of the Company, other than any documents or answers to
questions described in the subparagraph H above. 

  

	 	J.	The Subscriber acknowledges that the Subscriber has had an opportunity to read and review the Company’s organizational documents, as amended or restated, and its By-laws, as
amended or restated, and does hereby adopt and agree to be bound by them. 

  

	 	K.	The Subscriber has discussed or has had an opportunity to discuss with his professional legal, tax and financial advisors the suitability of an investment in the Company for his
particular tax and financial situation and confirms that, in making his decision to purchase the Units hereby subscribed for, he has relied as to legal and tax matters concerning his investment upon independent investigation made by him, and his own
professional tax and other advisors. All information which the Subscriber has provided to the Company concerning himself and his financial position is correct and complete as of the date set forth below, and if there should be any material change in
such information prior to the closing of the sale of Units, he will immediately provide such information to the Company. 

  

	 	L.	The Subscriber represents, warrants and agrees that he will not sell or otherwise transfer the Preferred Stock, the Warrants or the Underlying Shares without registration under the
Securities Act or an exemption therefrom and fully understands and agrees that he must bear the economic risk of his purchase because, among other reasons, the Preferred Stock, the Warrants and the Underlying Shares have not been registered under
the Securities Act or under the securities laws of any state and, therefore, cannot be resold, pledged, assigned or otherwise disposed of unless the applicable security is subsequently registered under the Securities Act and under applicable
securities laws of such states or an exemption from such registration is available. In particular, the Subscriber is aware that the Preferred Stock, the Warrants, and the Underlying Shares are “restricted securities,” as such term is
defined in Rule 144 promulgated under the Securities Act (“Rule 144”), and they may not be resold pursuant to Rule 144 unless all of the conditions of Rule 144 are met. The Subscriber also understands that, except as otherwise provided in
the Registration Rights Agreement referred to in the preamble to this Purchase Agreement, the Company is under no obligation to register the Preferred Stock, the Warrants or the Underlying Shares on his behalf or to assist him in complying with any
exemption from registration under the Securities Act or applicable state securities laws. The Subscriber further understands that sales or transfers of the Preferred Stock, the Warrants and the Underlying Shares are further restricted by state
securities laws and the provisions of this Agreement. 

  

	 	M.	The Subscriber consents to the placement of a restrictive legend on the certificate(s) for the Preferred Stock, Warrants and Underlying Shares as required by applicable securities
laws or otherwise. 

	 	N.	The Subscriber has not engaged any broker, dealer, finder, commission agent or other similar person in connection with the offer, offer for sale, or sale of the Units and is under
no obligation to pay any broker’s fee, or commission in connection with his investment. 

  

	 	O.	The address set forth is the Subscriber’s true and correct address, and the Subscriber has no present intention of becoming a resident of any other state of jurisdiction.

  

	 	P.	If this Agreement is executed and delivered on behalf of an individual or individuals, the Agreement constitutes a valid and legally binding obligation of the Subscriber. If this
Agreement is executed and delivered on behalf of a partnership, corporation, trust or other entity, the Subscriber has been duly authorized to execute and deliver this Agreement and all other instruments executed and delivered on behalf of such
partnership, corporation, trust or other entity in connection with the purchase of the Units and to make the representations and warranties made herein on behalf of such entity and that this investment in the Company has been affirmatively
authorized by the governing board of such entity and is not prohibited by the governing documents of such entity, the signature of the Subscriber is binding upon such partnership, trust or other entity and the Subscriber has delivered herewith, or
shall deliver upon request of the Company, the underlying partnership agreement, corporate charter documents or trust agreement of such entity and such other evidence of the ability of such partnership, corporation or trust to purchase the Units.

  

	 	Q.	The foregoing representations and warranties are true and accurate as of the date hereof and shall be true and accurate as of the date of acceptance hereof by the Company and the
issuance of the Preferred Stock and Warrants to the Subscriber. If in any respect such representations and warranties or any information contained herein or in the Investor Questionnaire shall not be true and accurate prior thereto, the Subscriber
will give written notice of such fact to the Company, specifying which representations and warranties or information are not true and accurate and the reason therefor. 

  

	3.	Indemnification. 

 The Subscriber agrees to
indemnify and hold harmless the Company, its officers and directors, employees and its affiliates and each other person, if any, who controls any thereof, against any loss, liability, claim, damage and expense whatsoever (including, but not limited
to, any and all expenses whatsoever reasonably incurred in investigating, preparing or defending against any litigation commenced or threatened or any claim whatsoever) arising out of or based upon any false representation or warranty or breach or
failure by the Subscriber to comply with any covenant or agreement made by the Subscriber herein or in any other document furnished by the Subscriber to any of the foregoing in connection with this transaction. 

	4.	Transferability. 

 The Subscriber agrees that
this Agreement, and any of his interest herein, is not assignable, and further agrees that any assignment or transfer of the Shares purchased by the Subscriber shall be made only in accordance with applicable federal and state securities laws.

  

	5.	Revocation. 

 The Subscriber agrees that he
shall not cancel, terminate or revoke this Agreement or any agreement made hereunder and that this Agreement shall survive the death or disability of the subscriber. 
  

	6.	Miscellaneous. 

  

	 	A.	Capitalized terms used in this Agreement, if not otherwise defined herein, shall have the respective meanings attributed to such terms in the Offering Documents.

  

	 	B.	Notices required or permitted to be given hereunder shall be in writing and shall be deemed to be sufficiently given when personally delivered or when sent by registered or
certified mail, return receipt requested, addressed to the other party at the address of such party set forth herein, or to such other address furnished by notice given in accordance with this paragraph. 

  

	 	C.	Failure of the Company to exercise any right or remedy under this Agreement or any other agreement between the Company and the Subscriber, or otherwise, or delay by the Company in
exercising same, will not operate as a waiver thereof. No waiver by the Company will be effective unless and until it is in writing and signed by the Company. 

  

	 	D.	This Agreement shall be enforced, governed and construed in all respects in accordance with the laws of the Commonwealth of Massachusetts. This Agreement and the rights, powers and
duties set forth herein shall be binding upon the Subscriber, the Subscriber’s heirs, estate, legal representatives, successors and assigns and shall inure to the benefit of the Company and its successors and assigns. In the event that any
provision of this Agreement is unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule
of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof. 

 [Signature Page Follows] 

 IN WITNESS WHEREOF, the Subscriber has executed this Agreement as of the
             day of                         , 2007.

  

					
	 Number of Units subscribed for (25,000 minimum):
	 		  	  

			
	Total purchase price ($1.00 per Share):	 	$	  	  

 If the Subscriber is an individual, please sign below: 
  

					
	Subscriber	 		 	Joint Subscriber, if any
			
	  
	 		 	  

	Authorized Signature of Subscriber	 		 	Authorized Signature of Joint Subscriber, if any
			
	  
	 		 	  

	Name of Subscriber	 		 	Name of Joint Subscriber, if any
	(Please Print)	 		 	(Please Print)
			
	  
	 		 	  

	Residence Street Address	 		 	Residence Street Address of Joint Subscriber, if any
			
	  
	 		 	  

	City or Town	 		 	City or Town
	State, Zip	 		 	State, Zip
			
	  
	 		 	  

	Social Security Number of Subscriber	 		 	Social Security Number of Joint Subscriber, if any

 If Joint Ownership, check one: 
              Joint Tenants with Right of Survivorship 
              Tenants in Common 
              Tenants by the Entirety 
 If the Subscriber is a partnership,
corporation, trust or other entity, please sign below. 
  

	
	  

	Name of Entity
	
	  

	Authorized signatory
	
	  

	Print name of signatory
	
	  

	Title
	
	  

	Tax Identification Number
	
	  

	Address

 Accepted this
             day of                         , 2007, on
behalf of the Company. 
  

			
	By:	 	  

	Name:	 	  

	Title:	 	  

 EXHIBIT 10.1 
 EXHIBIT A 
 Definition of “Accredited Investor” as Set Forth in Rule 501 of Regulation D
Promulgated Under the Securities Act 
 1. Director or Officer. The Subscriber is a director or executive officer or general partner of the
Company, or general partner of its general partner. 
 2. Natural Person—Annual Income Test. The Subscriber is a natural person who had
individual income (i.e., not including the Subscriber’s spouse’s income) in excess of $200,000 in each of the two most recent years and reasonably expects to have individual income in excess of $200,000 in the current year, or had joint
income, with the Subscriber’s spouse, in excess of $300,000 in each of the two most recent years and reasonably expects to have joint income, with the Subscriber’s spouse, in excess of $300,000 in the current year. 
 3. Natural Person—Net Worth Test. The Subscriber is a natural person whose individual net worth, or joint net worth with that of the Subscriber’s
spouse, at the time of the purchase exceeds $1,000,000. 
 4. Other Entities and Persons. The Subscriber is either: a bank as defined in
section 3(a)(2) of the Securities Act or any savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Securities Act whether acting in its individual or fiduciary capacity; any broker or dealer
registered pursuant to section 15 of the Securities Exchange Act of 1934; an insurance company as defined in section 2(13) of the Securities Act; an investment company registered under the Investment Company Act of 1940 or a
business development company as defined in section 2(a)(48) of that Act; a Small Business Investment Company licensed by the U.S. Small Business Administration under section 301(c) or (d) of the Small Business Investment Act of
1958; a plan established and maintained by a state, its political subdivisions or any agency or instrumentality of a state or its political subdivisions for the benefit of its employees, if such plan has total assets in excess of $5,000,000;
or an employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974, if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such Act, which is either a bank, savings and
loan association, insurance company or registered investment advisor, or if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made solely by persons that are accredited
investors. 
 5. Trust. The Subscriber is a trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the
offered securities, whose purchase is directed by a “sophisticated person” as defined in Rule 506(b)(2)(ii) under the Securities Act of 1993. 

 6. Private Business Development Company. The Subscriber is a private business development company as defined in
section 202(a)(22) of the Investment Advisers Act of 1940. 
 7. Business and Nonprofit Entities. The Subscriber is any organization described in
Section 501(c)(3) of the Internal Revenue Code, corporation, Massachusetts or similar business or trust partnership, not formed for the specific purpose of acquiring the securities, with total assets in excess of $5,000,000. 
 8. Entity Owned by Accredited Investors. The Subscriber is an entity in which all of the equity owners would qualify as Accredited Investors above.Form of Registration Rights Agreement

 EXHIBIT 10.2 
 REGISTRATION RIGHTS AGREEMENT 
 THIS REGISTRATION RIGHTS AGREEMENT (this
“Agreement”) is made and entered into as of                     , 2007, by and among Pro-Pharmaceuticals, Inc., a Nevada
corporation (the “Issuer”), [the Persons (as defined below) whose names appear on the signature pages hereto] (the “Holders”). 
 WHEREAS, pursuant to the terms of a Securities Purchase Agreement, dated on or about the date hereof, by and among the Issuer and the Holders (the “Purchase Agreement”), the Issuer has agreed to issue
to the Holders an aggregate of 5,000,000 shares of unregistered Series A preferred stock, par value $0.01 per share, of the Issuer (the “Preferred Shares”), which are convertible into a like number of shares the common stock, $.001
par value per share (the “Common Stock”), on a one-for-one basis of the Issuer (the “Conversion Shares”); 
 WHEREAS, pursuant to the terms of the Purchase Agreement, the Issuer, as to each Preferred Share purchased thereunder, each Holder will receive (i) a warrant to purchase one share of the Common Stock, par value $0.01 per share, of the
Issuer (the “Common Stock”) at a purchase price of $1.50 per share, and (ii) a warrant exercisable to purchase one share of Common Stock at a purchase price of $2.00 per share (collectively, the “Warrants”, and
the shares of Common Stock issuable thereunder, the “Warrant Shares”); 
 WHEREAS, it is a condition to the terms of the
transaction contemplated by the Purchase Agreement and the Warrants that the Issuer and the Holders execute this Agreement; 
 NOW,
THEREFORE, the parties hereto agree as follows: 
 Section 1. Definitions 
 As used in this Agreement: 
 (a)
“Person” shall mean an individual, partnership, corporation, limited liability company, association, trust, joint venture, unincorporated organization or other entity, and any government, governmental department or agency or
political subdivision thereof. 
 (b) the terms “register,” “registered” and
“registration” refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act (and any post-effective amendments filed or required to be filed) and the declaration or ordering
of effectiveness of such registration statement; 
 (c) the term “Registrable Securities” means the Conversion Shares and
the Warrant Shares; 

 (d) “Registration Expenses” shall mean all expenses incurred by the Issuer in compliance
with Section 2 hereof, including, without limitation, all registration and filing fees, printing expenses, fees and disbursements of counsel for the Issuer, blue sky fees and expenses and the expense of any special audits incident to or
required by any such registration (but excluding the compensation of regular employees of the Issuer, which shall be paid in any event by the Issuer); 
 (e) “SEC” shall mean the Securities and Exchange Commission. 
 (f) “Securities
Act” shall mean the Securities Act of 1933, as amended. 
 (g) “Selling Expenses” shall mean, with respect to a
given Holder, all underwriting discounts and selling commissions applicable to the sale of the Registrable Securities of such Holder and all fees and disbursements of counsel to such Holder. 
 Section 2. Form S-3 
 The Issuer shall
file, within six (6) months after the closing of the offering contemplated by the Purchase Agreement, a registration statement on Form S-3 with the SEC to register the Registrable Securities, and use commercially reasonable efforts, including
filing any amendments to such registration statement in response to comments of the staff of the SEC, to have such registration statement declared effective by the SEC as soon as reasonably possible. Each Holder desiring to register Registrable
Securities must timely deliver to the Issuer a duly completed and signed Selling Securityholder Notice and Questionnaire in the form of Annex A hereto. 
 Section 3. Expenses of Registration 
 All Registration Expenses incurred in connection with any
registration, qualification or compliance pursuant to this Agreement shall be borne by the Issuer, and any and all Selling Expenses of a given Holder shall be borne by such Holder. 
 Section 4. Registration Procedures 
 In the case of each registration effected by the Issuer pursuant to this Agreement, the Issuer will keep each Holder advised in writing as to the initiation of each registration and as to the completion thereof. At its expense, the Issuer
will: 
 (a) if necessary to facilitate the sale of all of the Registrable Securities, keep such registration effective until all Warrant
Shares may be resold under Rule 144(k) of the Securities Act; and 
 (b) furnish such number of prospectuses and other documents incident
thereto to a Holder as such Holder from time to time may reasonably request. 
 Section 5. Indemnification 
 (a) The Issuer will indemnify each Holder and each of its officers and directors, as applicable, with respect to each registration which has been effected
pursuant to this 

 
Agreement, and each underwriter, if any, and each person who controls any underwriter, against all claims, losses, damages and liabilities (or actions in
respect thereof) arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any prospectus, offering circular or other document (including any related registration statement, notification or the
like) incident to any such registration, qualification or compliance, or based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or any
violation by the Issuer of the Securities Act or any rule or regulation thereunder applicable to the Issuer and relating to action or inaction required of the Issuer in connection with any such registration, qualification or compliance, and will
reimburse each Holder and its directors and officers, as applicable, for any legal or any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability or action; provided that the
Issuer will not be liable in any such case to the extent that any such claim, loss, damage, liability or expense arises out of or is based on any untrue statement or omission based upon written information furnished to the Issuer by a Holder or
underwriter. 
 (b) Each Holder will, if Registrable Securities held by it are included in the securities as to which such registration,
qualification or compliance is being effected, indemnify the Issuer, each of its directors and officers and each underwriter, if any, of the Issuer’s securities covered by such a registration statement, each person who controls the Issuer or
such underwriter, each other stockholder of the Issuer participating in such registration, and each of their respective officers, directors, and partners, and each person controlling such other stockholder, in each case, against all claims, losses,
damages and liabilities (or actions in respect thereof) arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any such registration statement, prospectus, offering circular or other document
made by such Holder, or any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements by such Holder therein not misleading, and will reimburse the Issuer and such other
stockholders, directors, officers, members, partners, persons, underwriters or control persons for any legal or any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability or action,
in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus, offering circular or other document in reliance upon
and in conformity with written information furnished to the Issuer by such Holder. 
 (c) Each party entitled to indemnification under this
Section 5 (the “Indemnified Party”) shall give notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim
as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom; provided that counsel for the Indemnifying Party, who shall conduct the defense of
such claim or any litigation resulting therefrom, shall be approved by the Indemnified Party (whose approval shall not unreasonably be withheld) and the Indemnified Party may participate in such defense at such party’s expense (unless the
Indemnified Party shall have reasonably concluded that there may be a conflict of interest between the Indemnifying Party and the Indemnified Party in such action, in which case the fees and expenses of counsel shall be at the expense of the
Indemnifying Party), and provided further that the failure of any Indemnified Party to give notice as provided herein shall 

 
not relieve the Indemnifying Party of its obligations under this Agreement unless the Indemnifying Party is materially prejudiced thereby. No Indemnifying
Party, in the defense of any such claim or litigation shall, except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the
claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation. Each Indemnified Party shall furnish such information regarding itself or the claim in question as an Indemnifying Party may
reasonably request in writing and as shall be reasonably required in connection with the defense of such claim and litigation resulting therefrom. 
 (d) If the indemnification provided for in this Section 5 is held by a court of competent jurisdiction to be unavailable to an Indemnified Party with respect to any loss, liability, claim, damage or expense referred to herein, then the
Indemnifying Party, in lieu of indemnifying such Indemnified Party hereunder, shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate
to reflect the relative fault of the Indemnifying Party on the one hand and of the Indemnified Party on the other in connection with the statements or omissions which resulted in such loss, liability, claim, damage or expense, as well as any other
relevant equitable considerations. The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things, whether the untrue (or alleged untrue) statement of a material fact or the omission
(or alleged omission) to state a material fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such
statement or omission. 
 (e) Notwithstanding the foregoing and subject to Section 5(g) hereof, to the extent that the provisions on
indemnification and contribution contained in the underwriting agreement entered into by, inter alia, the Holders in connection with any underwritten public offering contemplated by this Agreement are in conflict with the foregoing
provisions, the provisions in such underwriting agreement shall be controlling. 
 (f) The foregoing indemnity agreement of the Issuer and
the Holders is subject to the condition that, insofar as they relate to any loss, claim, liability or damage made in a preliminary prospectus but eliminated or remedied in the amended prospectus on file with the SEC at the time the registration
statement in question becomes effective or the amended prospectus filed with the SEC pursuant to SEC Rule 424(b) (the “Final Prospectus”), such indemnity agreement shall not inure to the benefit of any underwriter if a copy of the
Final Prospectus was furnished to the underwriter and was not furnished to the person asserting the loss, liability, claim or damage at or prior to the time such action is required by the Securities Act. 
 (g) Notwithstanding any provision of this Agreement or in any underwriting agreement contemplated hereby, in accordance with Section 17(i) if the
Investment Company Act of 1940, as amended, any provision in an underwriting agreement to be entered into in connection with the registration of Shares pursuant to this Agreement which protects or purports to protect the underwriter or underwriters
against any liability to the Issuer or its security holders to which such underwriter(s) would otherwise be subject by reason of willful misfeasance, bad faith 

 
or gross negligence in the performance of their duties or by reason of such underwriter(s) reckless disregard of their obligations and duties under the
underwriting agreement shall be expressly made inapplicable to the Issuer. 
 Section 6. Information by the Holders 
 Each Holder shall furnish to the Issuer such information regarding such Holder and the distribution proposed by such Holder as the Issuer may reasonably
request in writing and as shall be reasonably required in connection with any registration, qualification or compliance referred to in this Agreement. 
 Section 7. Rule 144 Reporting 
 With a view to making available the benefits of certain rules and
regulations of the SEC which may permit the sale of restricted securities to the public without registration, the Issuer agrees to: 
 (a)
make and keep public information available as those terms are understood and defined in Rule 144 at all times; 
 (b) use its commercially
reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Issuer under the Securities Act and the Exchange Act; and 
 (c) so long as a Holder owns any Registrable Securities, furnish to such Holder upon request a written statement by the Issuer as to its compliance with the reporting requirements of Rule 144 and of the Securities Act
and the Exchange Act, a copy of the most recent annual or quarterly report of the Issuer, and such other reports and documents so filed as such Holder may reasonably request and as is necessary for such Holder to avail itself of any rule or
regulation of the SEC allowing such Holder to sell any of such securities without registration. 
 Section 8. Market Stand-off
Agreement 
 Each Holder agrees, if requested by the Issuer and an underwriter of the Common Stock (or other securities) of the Issuer,
not to sell or otherwise transfer or dispose of any Common Stock (or other securities of the Issuer) held by the Holder during the 90-day period following the effective date of a registration statement of the Issuer filed under the Securities Act;
provided, however, that the Issuer shall not make such a request unless all similarly situated selling securityholders (regardless of the number of shares owned) are to be restricted in the same manner (including duration and nature of transfer
restrictions) without discrimination and the Issuer accompanies such request with an officer’s certificate identifying the other securityholders to be bound by such an agreement. If requested by the underwriters, each such Holder shall execute
a separate agreement to the foregoing effect. The Issuer may impose stop-transfer instructions with respect to the shares (or securities) subject to the foregoing restriction until the end of said 90-day period. The provisions of this Section 8
shall be binding upon any transferee who acquires Registrable Securities, whether or not such transferee is entitled to the registration rights provided hereunder. 

 Section 9. Miscellaneous 
 (a) Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachustts applicable to
contracts made and to be performed entirely within such State without regard to principles of conflicts of law. 
 (b) Paragraph and
Section Headings. The descriptive headings of the several sections of this Agreement are inserted for convenience only and shall not control or affect the meaning or construction of any of the provisions hereof. 
 (c) Notices. All notices, demands or other communications to be given or delivered under or by reason of the provisions of this Agreement shall be in
writing and shall be deemed to have been given (i) when delivered personally to the recipient, (ii) when sent to the recipient by telecopy (receipt electronically confirmed by sender’s telecopy machine) if during normal business hours
of the recipient, otherwise on the next business day, (iii) one business day after the date when sent to the recipient by reputable express courier service (charges prepaid), or (iv) seven business days after the date when mailed to the
recipient by certified or registered mail, return receipt requested and postage prepaid. Such notices, demands and other communications shall be sent to the Holders and to the Issuer at the addresses indicated below: 
  

			
	 If to a Holder:
	 	To the address of such Holder set forth on
		 	the signature pages to this agreement.
		
	If to the Issuer:	 	Pro-Pharmaceuticals, Inc.
		 	7 Wells Avenue
		 	Newton, Massachusetts 02459
		 	Attn: Anthony D. Squeglia, Chief Financial Officer
		 	Fax.: (617) 928-3450

  

			
	 With a copy to:
 (which shall
 not constitute
 notice)
	 	Greenberg Traurig, LLP
	 	1 International Place
	 	Boston, MA 02110
	 	Attention: Jonathan C. Guest, Esq.
	 	Fax.: (617) 897-0966

 or to such other address as a party hereto may, from time to time, designate in writing delivered pursuant to the
terms of this Section. 
 (d) Amendments. The terms, provisions and conditions of this Agreement may not be changed, modified or
amended in any manner except by an instrument in writing duly executed by each of the parties hereto. 
 (e) Assignment. Neither this
Agreement nor any of the rights, duties, or obligations of any party hereunder may be assigned or delegated (by operation of law or otherwise) by either party hereto except with the prior written consent of the other party hereto; 

 
provided, however, that a Holder may assign or delegate its rights, duties and obligations hereunder to any transferee of such Holder’s Registrable
Securities who agrees in writing to become bound by the terms and conditions of this Agreement, so long as such assignment or delegation is not in violation of any applicable law or regulation. 
 (f) Counterparts. For the convenience of the parties, any number of counterparts of this Agreement may be executed by any one or more parties
hereto, and each such executed counterpart shall be, and shall be deemed to be, an original, but all of which shall constitute, and shall be deemed to constitute, in the aggregate but one and the same instrument. 
 (g) Entire Agreement. This Agreement embodies the entire agreement and understanding of the parties hereto in respect of the subject matter
hereof. There are no restrictions, promises, representations, warranties, covenants or undertakings, other than those expressly set forth or referred to herein. 
 [Signature Pages Follow] 

 IN WITNESS WHEREOF, each of the parties hereto has caused this Registration Rights Agreement to be
executed on its behalf by its officers thereunto duly authorized, all as of the day and year first above mentioned. 
  

					
	 ISSUER:
	 	PRO-PHARMACEUTICALS, INC.
			
		 	By:	 	  

		 	Name:	 	Anthony D. Squeglia
		 	Title:	 	Chief Financial Officer

  

					
	 HOLDERS:
	 	
		 		 	Address for Notices:
			
	By:	 	  
	 	
	Name:	 		 	
	Title:	 		 	

 Registration Rights Agreement 

 EXHIBIT 10.2 
 EXHIBIT A 
  

							
		 	Holder	 	Shares	 	

 EXHIBIT 10.2 
 Annex A 
 PRO-PHARMACEUTICALS, INC. 
 Selling Securityholder Notice and Questionnaire 
 The undersigned beneficial
owner of Series A Convertible Preferred Stock, par value $0.01 per share (the “Common Stock”), of Pro-Pharmaceuticals, Inc., a Nevada corporation (the “Company”), (the “Registrable Securities”) understands
that the Company has filed or intends to file with the Securities and Exchange Commission (the “Commission”) a registration statement on Form [S-3 (the “Registration Statement”) for the registration and resale under
Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”), of the Registrable Securities, in accordance with the terms of the Registration Rights Agreement (the “Registration Rights Agreement”),
among the Company and the Holders named therein. A copy of the Registration Rights Agreement is available from the Company upon request at the address set forth below. All capitalized terms not otherwise defined herein shall have the meanings
ascribed thereto in the Registration Rights Agreement. 
 Certain legal consequences arise from being named as a selling securityholder in
the Registration Statement and the related prospectus. Accordingly, holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a
selling securityholder in the Registration Statement and the related prospectus. 
 NOTICE 
 The undersigned beneficial owner (the “Selling Securityholder”) of Registrable Securities hereby elects to include the Registrable
Securities owned by it and listed below in Item 3 (unless otherwise specified under such Item 3) in the Registration Statement. 

 The undersigned hereby provides the following information to the Company and represents and warrants that such
information is accurate: 
 QUESTIONNAIRE 
 1. Name. 

			
	(a)	  	Full Legal Name of Selling Securityholder
		
		  	  

		
	(b)	  	Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities Listed in Item 3 below are held:
		
		  	  

		
	(c)	  	Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to vote or dispose of the securities covered by the
questionnaire):
		
		  	  

 2. Address for Notices to Selling Securityholder: 
  

	
	  

	  

	  

  

			
	Telephone:	 	  

			
	Fax:	 	  

			
	Contact Person:	 	  

 3. Beneficial Ownership of Registrable Securities: 
  

			
	(a)	  	Type and Principal Amount of Registrable Securities beneficially owned (not including the Registrable Securities that are issuable pursuant to the Purchase Agreement):
		
		  	  

		  	  

		  	  

 4. Broker-Dealer Status: 
  

					
	(a)	 	Are you a broker-dealer?
		
		 	 Yes  q        No  q

		
	(b)	 	If “yes” to Section 4(a), did you receive your Registrable Securities as compensation for investment banking services to the Company.
		
		 	 Yes  q        No  q

		
	Note:	 	If no, the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.
		
	(c)	 	Are you an affiliate of a broker-dealer?
		
		 	 Yes  q        No  q

		
	(d)	 	If you are an affiliate of a broker-dealer, do you certify that you bought the Registrable Securities in the ordinary course of business, and at the time of the purchase of the
Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities?
		
		 	 Yes  q        No  q

		
	Note:	 	If no, the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.

 5. Beneficial Ownership of Other Securities of the Company Owned by the Selling Securityholder. 

Except as set forth below in this Item 5, the undersigned is not the beneficial or registered owner of any securities of the Company other than
the Registrable Securities listed above in Item 3. 
  

					
	(a)    	 	Type and Amount of Other Securities beneficially owned by the Selling Securityholder:
		 	  

		 	  

 6. Relationships with the Company: 
  

	
	Except as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the equity securities of the
undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors or affiliates) during the past three years.
	
	State any exceptions here:
	
	  

	  

 The undersigned agrees to promptly notify the Company of any inaccuracies or changes in the information provided
herein that may occur subsequent to the date hereof at any time while the Registration Statement remains effective. 
 By signing below, the
undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 6 and the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto.
The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment of the Registration Statement and the related prospectus. 
 IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person or by
its duly authorized agent. 
  

							
	 Dated:
	 	  
	 	Beneficial Owner:	 	  

							
				
		 		 	By:	 	

		 		 	Name:	 	
		 		 	Title:	 	

 PLEASE FAX A COPY OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE, AND RETURN THE ORIGINAL BY OVERNIGHT
MAIL, TO: 
 Anthony Squeglia 
 Chief Financial Officer

 Pro-Pharmaceuticals, Inc. 
 7 Wells Avenue 
 Newton, MA 02459 
 Fax: 617-928-3450

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}]]